- Net cash used in operating and investing activities was
$12.0 million in the third quarter and net cash used in operating and investing activities was$8.9 million for the first nine months of 2026; quarter-end cash and restricted cash position was$272.2 million - Novo recently presented post hoc analyses at the
Heart Failure Society of America (HFSA) AnnualScientific Meeting from the coramitug Phase 2 trial which demonstrated a decrease of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) in patients treated with coramitug as compared to an increase in patients on placebo, further supporting the potential of coramitug as a treatment for ATTR-CM - Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months
“During the quarter, Roche and Novo highlighted prasinezumab at Roche’s Pharma Day and coramitug at Novo’s Capital Markets Day, underscoring the potential of these
Business Highlights and Upcoming Milestones
Clinical Development Portfolio
Prasinezumab, a potential first-in-class antibody for the treatment of Parkinson’s disease that is designed to target a key epitope within the C-terminus of alpha-synuclein and is the focus of a worldwide collaboration with Roche.
- Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants for a minimum of 104 weeks with early-stage Parkinson's disease on stable symptomatic monotherapy with levodopa; primary completion expected in 2029 (NCT07174310)
- Roche has stated that prasinezumab has peak sales potential greater than
$3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson’s disease—a condition that affects 10 million people worldwide
Coramitug (formerly PRX004), a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein, is being developed by Novo as part of its up to
- Novo is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)
- Novo recently presented post hoc analyses of its Phase 2 coramitug trial at the HFSA Annual Scientific Meeting. At week 52, the pooled coramitug dose groups (10 and 60 mg/kg) reported an ~8% decrease of the inflammatory biomarker hsCRP, compared with an ~33% increase with placebo (treatment ratio versus placebo: 0.66; nominal p=0.0269)
- Open-label study ongoing to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)
- Coramitug granted Fast Track designation from the
U.S . FDA for the treatment of ATTR-CM
Moponetug (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer’s disease that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of Alzheimer’s disease.
- Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 clinical trial in approximately 310 patients with early Alzheimer’s disease; expected data readout in 1H 2027 (NCT06268886)
- Bristol Myers Squibb is conducting a Phase 1, open-label, multi-part study to evaluate pharmacokinetics, absolute bioavailability, safety, tolerability, and immunogenicity of single-dose moponetug following intravenous and subcutaneous administrations in healthy adults and multiple doses of moponetug in participants with early Alzheimer's disease; primary completion expected mid-2027 (NCT07780383)
- Bristol Myers Squibb conducted a Phase 1 open-label single-dose clinical trial to assess a subcutaneous administration (NCT06955741)
- Moponetug granted Fast Track designation by
U.S . FDA as a treatment for Alzheimer’s disease
Preclinical Development Portfolio
TDP-43 CYTOPE®, a wholly-owned proprietary preclinical program for precision intracellular targeting of TDP-43 pathology, a defining pathogenic feature of ALS and other TDP-43 proteinopathies. TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena’s CYTOPE technology to target intracellular disease pathways.
Prothena presented a poster at Neuroscience 2025 (Society for Neuroscience ), as well as encore presentations at the International Symposium of ALS/MND 2025 and the 2026 European Network to Cure ALS (ENCALS) demonstrating the activity of TDP-43 CYTOPE in multiple preclinical models
PRX012-TfR, a wholly-owned preclinical program combining PRX012, our single-injection, once-monthly antibody delivered subcutaneously with proprietary transferrin receptor technology to potentially improve its product profile for the treatment of Alzheimer’s disease.
- Preclinical studies ongoing to support potential efficacy of PRX012-TfR
Third Quarter of 2026 Financial Results
For the third quarter and first nine months of 2026,
Research and development (R&D) expenses totaled
General and administrative (G&A) expenses totaled
Total non-cash share-based compensation expense was
As of
As of
2026 Financial Guidance
The Company continues to expect its full year 2026 net cash used in operating and investing activities to be
3Q 2026 Share Repurchase Program
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Amyotrophic lateral sclerosis (ALS). Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of our pipeline and completion of our ongoing clinical trials; the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of our CYTOPE® technology and expected milestones in 2027, and beyond; the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab, coramitug, moponetug, TDP-43 CYTOPE, and PRX012-TfR; plans for ongoing and future clinical trials of prasinezumab, coramitug, and moponetug; the expected timing of reporting data from preclinical studies and clinical trials; projections regarding peak sales and patient population for prasinezumab; amounts we may receive under our collaborations with Roche, Novo, and Bristol Myers Squibb; our anticipated net cash burn from operating and investing activities for 2026 and expected cash balance at the end of 2026; our estimated net loss and non-cash share-based compensation expense for 2026; and the potential to return capital to shareholders via a share repurchase program or other permissible means. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
| ||||||||||||||||
|
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
Collaboration revenue |
| $ | 620 |
|
| $ | 2,415 |
|
| $ | 2,664 |
|
| $ | 9,613 |
|
Revenue from license and intellectual property |
|
| — |
|
|
| — |
|
|
| 50,050 |
|
|
| 50 |
|
Total revenue |
|
| 620 |
|
|
| 2,415 |
|
|
| 52,714 |
|
|
| 9,663 |
|
Operating expenses: |
|
|
|
|
|
|
|
| ||||||||
Research and development |
|
| 8,427 |
|
|
| 28,938 |
|
|
| 29,852 |
|
|
| 120,266 |
|
General and administrative |
|
| 10,594 |
|
|
| 13,238 |
|
|
| 34,159 |
|
|
| 46,746 |
|
Restructuring costs |
|
| 420 |
|
|
| 479 |
|
|
| (1,410 | ) |
|
| 33,088 |
|
Total operating expenses |
|
| 19,441 |
|
|
| 42,655 |
|
|
| 62,601 |
|
|
| 200,100 |
|
Loss from operations |
|
| (18,821 | ) |
|
| (40,240 | ) |
|
| (9,887 | ) |
|
| (190,437 | ) |
Other income, net |
|
| 2,314 |
|
|
| 3,328 |
|
|
| 7,521 |
|
|
| 11,187 |
|
Loss before income taxes |
|
| (16,507 | ) |
|
| (36,912 | ) |
|
| (2,366 | ) |
|
| (179,250 | ) |
Provision for (benefit from) income taxes |
|
| 2 |
|
|
| (371 | ) |
|
| 5 |
|
|
| 43,253 |
|
Net loss |
| $ | (16,509 | ) |
| $ | (36,541 | ) |
| $ | (2,371 | ) |
| $ | (222,503 | ) |
Basic and diluted net loss per ordinary share |
| $ | (0.32 | ) |
| $ | (0.68 | ) |
| $ | (0.05 | ) |
| $ | (4.13 | ) |
Shares used to compute basic and diluted net loss per share |
|
| 51,437 |
|
|
| 53,830 |
|
|
| 52,422 |
|
|
| 53,828 |
|
| |||||
|
| ||||
| 2026 |
| 2025 | ||
Assets |
|
|
| ||
Cash and cash equivalents | $ | 271,368 |
| $ | 307,531 |
Prepaid expenses and other current assets |
| 2,494 |
|
| 7,662 |
Total current assets |
| 273,862 |
|
| 315,193 |
Property and equipment, net |
| 2,299 |
|
| 2,144 |
Operating lease right-of-use assets |
| 6,017 |
|
| 8,125 |
Restricted cash, non-current |
| 860 |
|
| 860 |
Other non-current assets |
| 482 |
|
| 482 |
Total non-current assets |
| 9,658 |
|
| 11,611 |
Total assets | $ | 283,520 |
| $ | 326,804 |
Liabilities and Shareholders’ Equity |
|
|
| ||
Accrued research and development | $ | 489 |
| $ | 4,329 |
Deferred revenue, current |
| — |
|
| 2,664 |
Restructuring liability |
| 587 |
|
| 13,303 |
Lease liability, current |
| 3,007 |
|
| 2,886 |
Other current liabilities |
| 7,351 |
|
| 17,661 |
Total current liabilities |
| 11,434 |
|
| 40,843 |
Lease liability, non-current |
| 3,249 |
|
| 5,487 |
Total non-current liabilities |
| 3,249 |
|
| 5,487 |
Total liabilities |
| 14,683 |
|
| 46,330 |
Total shareholders’ equity |
| 268,837 |
|
| 280,474 |
Total liabilities and shareholders’ equity | $ | 283,520 |
| $ | 326,804 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105178540/en/
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
Source: